Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib.

Détails

ID Serval
serval:BIB_B559CC883586
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib.
Périodique
European Journal of Cancer
Auteur(s)
Montemurro M., Schöffski P., Reichardt P., Gelderblom H., Schütte J., Hartmann J.T., von Moos R., Seddon B., Joensuu H., Wendtner C.M., Weber E., Grünwald V., Roth A., Leyvraz S.
ISSN
1879-0852[electronic]
Statut éditorial
Publié
Date de publication
2009
Volume
45
Numéro
13
Pages
2293-2297
Langue
anglais
Résumé
Patients diagnosed with advanced gastrointestinal stromal tumours (GISTs) who are resistant or intolerant to both imatinib and second-line sunitinib have a poor prognosis and few therapeutic options. We evaluated the efficacy of nilotinib, a novel tyrosine kinase inhibitor (TKI) in patients pretreated with imatinib and sunitinib. Fifty-two consecutive patients treated with oral nilotinib, 400mg twice daily, within the nilotinib compassionate use programme in 12 European cancer centres, were included in this retrospective analysis. Median age was 59 years (range 24-80), and all patients had WHO performance score better than 3. All patients had failed both imatinib and sunitinib pretreatment, either due to progressing GIST (96%) or intolerance (4%). Five patients (10%; 95% confidence interval (CI) 2-18) responded to nilotinib and 19 patients (37%; 95% CI 24-50) achieved a disease stabilisation. Nilotinib was generally well tolerated, but six patients (12%) discontinued treatment due to intolerance. Median progression-free survival of nilotinib treatment was 12 weeks (95% CI 9-15; range 0-104) and median overall survival was 34 weeks (95% CI 3-65; range 2-135). Nilotinib is active in GIST resistant to both imatinib and sunitinib. These results warrant further investigation of nilotinib in GIST.
Mots-clé
Adult, Aged, Aged, 80 and over, Antineoplastic Agents/administration & dosage, Antineoplastic Agents/adverse effects, Disease-Free Survival, Drug Resistance, Neoplasm, Female, Gastrointestinal Stromal Tumors/drug therapy, Gastrointestinal Stromal Tumors/mortality, Humans, Indoles/adverse effects, Male, Middle Aged, Patient Selection, Piperazines/adverse effects, Pyrimidines/administration & dosage, Pyrimidines/adverse effects, Pyrroles/adverse effects, Retrospective Studies, Treatment Outcome, Young Adult
Pubmed
Web of science
Création de la notice
29/09/2009 9:19
Dernière modification de la notice
20/08/2019 15:23
Données d'usage